Compare Neurocrine Biosciences Inc (NBIX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Yum! Brands, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $142.39 (market cap $14.36B), while Yum! Brands, Inc. trades at $145.09 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 2.7× Neurocrine Biosciences Inc's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Yum! Brands, Inc. for 132 Days on average.
| NBIX | YUM | |
|---|---|---|
Market Cap | $14.36B | $39.02B |
Volume | 1,237,180 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $168.16 |
52-Week Low | $123.10 | $135.77 |
Typical Hold Time | 23 Days | 132 Days |
Enterprise Value | $14.37B | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
YUM stock trades at $145.15, up 3.42% today, with a bullish technical signal and strong support at $141. Revenue grew to $8.21B in 2025, with net income of $1.56B and a 25.4% net margin. The company recently sold Pizza Hut for $1.5B, focusing on KFC and Taco Bell, and declared a $0.75 dividend payable September 18, 2026.
Outlook is positive with a consensus price target of $170.44, though high debt and competitive pressures pose risks. Earnings beat expectations in two of the last three quarters, and cash flow from operations is robust at $2.01B, supporting shareholder returns amid a hold-heavy analyst rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
